{
    "prompt": "\n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: \n    The following is a summarized molecular profile from MSK-IMPACT.\n    Based on this profile, answer with the appropriate treatments for this patient in the format above.\n    Patient ID: P-0002524\nAge: 74\nGender: Female\nSample ID: P-0002524-T01-IM3\nGene Panel: IMPACT341\nCancer Type: Lung Adenocarcinoma\nSample Type: Metastasis\nTumor Purity: 50.0%\n=============\nDNA Variants:\nEGFR c.2573T>G (p.L858R) - in 59.00% of 668 reads\nKRAS c.183A>C (p.Q61H) - in 4.00% of 327 reads\nKRAS c.64C>A (p.Q22K) - in 3.00% of 344 reads\nPTPRT c.577C>T (p.P193S) - in 12.00% of 287 reads\nTP53 c.488A>G (p.Y163C) - in 25.00% of 252 reads\nCNA Data:\nEGFR - High Level Amplification\nStructural Variants:\nNo structural variant data found.\n    ",
    "response": "{\n  \"Status\": \"success\",\n  \"Treatment 1\": {\n    \"Disease Name\": \"Non-small cell lung cancer (NSCLC)\",\n    \"Disease Phase or Condition\": \"Metastatic NSCLC with EGFR exon 21 p.L858R mutation\",\n    \"Drug Name\": \"Osimertinib\",\n    \"Prior Treatment or Resistance Status\": \"First-line treatment (approved for first-line therapy in metastatic NSCLC with EGFR exon 19 deletions or exon 21 p.L858R variants)\",\n    \"Genomic Features\": \"EGFR c.2573T>G (p.L858R)\",\n    \"FDA-approval status\": \"FDA-approved for first-line treatment of metastatic NSCLC with EGFR exon 19 deletions or exon 21 p.L858R variants\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf\"\n  }\n}"
}